Risk factors
PharmaCyte Biotech (PMCB) risk factors
Item 1A of every PharmaCyte Biotech, Inc. 10-K on file, and what changed from one year to the next.
- FY2026 10-K risk factors
76 risks, 7 new, 4 dropped, 6 reworded since the prior year. New risks focus on FDA delays, Nasdaq’s $5 million MVLS rule, Series C preferred-stock seniority, and dependence on Singapore-based manufacturing.
Filed Jul 29, 2026 - FY2025 10-K risk factors
73 risks. PharmaCyte Biotech relies entirely on its unapproved Cell-in-a-Box technology for cancer treatment, facing substantial capital needs, manufacturing dependencies on Austrianova, and significant clinical trial hurdles.
Filed Aug 11, 2025